4D Molecular Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $85.2M | $37,000 | $20.7M | $3.1M | $18.0M |
| Operating income | -$159.5M | -$187.8M | -$112.9M | -$110.0M | -$71.3M |
| Operating expenses | $244.8M | $187.9M | $133.6M | $113.2M | $89.4M |
| Cash from operations | -$109.1M | -$134.6M | -$75.8M | -$86.7M | -$69.1M |
| Capital expenditure | $536,000 | $3.8M | $2.8M | $11.5M | $9.1M |
| Free cash flow | -$109.6M | -$138.4M | -$78.6M | -$98.2M | -$78.2M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $566.7M | $560.4M | $339.9M | $261.8M | $353.5M |
| Total liabilities | $61.0M | $49.8M | $32.1M | $30.5M | $34.4M |
Shares outstanding 52.3M · Free float 74.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.